Eugia Pharma Industria Farmaceutica Pharmaceutical Import Profile — Brazil (DGFT 2022–2026)

Name: Eugia Pharma Industria Farmaceutica Pharmaceutical Import Records from India — 2 Products, $3.2M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Eugia Pharma Industria Farmaceutica — Pharmaceutical Importer Profile (2026) | 2 Products, $3.2M Trade | TransData Nexus

Eugia Pharma Industria Farmaceutica

Pharmaceutical Importer · Brazil · Advanced Antibiotics Focus · $3.2M Total Trade · DGFT Verified

Eugia Pharma Industria Farmaceutica is a pharmaceutical importer based in Brazil with a total trade value of $3.2M across 2 products in 1 therapeutic categories. Based on 74 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Eugia Pharma Industria Farmaceutica sources from 2 verified Indian suppliers, with Aurobindo Pharma Limited accounting for 81.1% of imports.

Eugia Pharma Industria Farmaceutica — Import Portfolio & Supplier Network

Eugia Pharma Industria Farmaceutica import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Eugia Pharma Industria Farmaceutica?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Aurobindo Pharma Limited	$7.1M	245	81.1%
Eugia Pharma Specialities Limited	$1.7M	65	18.9%

Eugia Pharma Industria Farmaceutica sources from across .

What Formulations Does Eugia Pharma Industria Farmaceutica Import?

Formulation	Value	Ships
Cefazolin for injection 1g(cefazolin	$700.0K	14
Amoxicillin clavulanate potassium forinjection 1 2GM amoxicillina clavulanatodo potaissio 1g 200MG 10 s	$200.0K	4
Cefazolin for injection 1g (cefazolina s??dica 1g) (qty-9313pac	$149.5K	3
Cefazolin for injection 1g (cefazolina sadica 1g) (qty-9274 pac	$149.1K	3
Cefazolin for injection 1g (cefazolina sa3dica 1g) (qty-9225pac	$148.9K	3
Cefuroxime sodium for injection	$118.4K	6
Ertapenem for injection 1	$100.0K	2
Ampicillin and sulbactam for injection	$100.0K	2
Ertapenem for injection 1 g/vial	$100.0K	2
Ceftriaxone for injection 1g (ceftriaxone for injection USP 1g) (qty-5665pac	$99.6K	3
Ceftriaxone for injection 1g (ceftriaxone for injection USP 1g) (qty-5679 pac)	$97.3K	3
Cefepime for injection 1000MG (cloridrato de cefepima 1g) (qty-2928 pac	$93.8K	3
Cefepime for injection 1000MG (cloridrato de cefepima 1g) (qty-2930 pac	$93.2K	3
Cefazolin for injection 1g (cefazolina s?3dica 1g) (qty-4873 pac	$92.2K	3
Cefepime for injection 2000MG(cefepime	$90.7K	2

Eugia Pharma Industria Farmaceutica imports 195 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ceftriaxone	Advanced Antibiotics	$2.1M	53	0.7%	10
2	Ertapenem	Advanced Antibiotics	$1.1M	21	1.0%	9

Eugia Pharma Industria Farmaceutica imports 2 pharmaceutical products across 1 categories into Brazil totaling $3.2M.

Eugia Pharma Industria Farmaceutica — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Eugia Pharma Industria Farmaceutica Ltda., established on December 20, 2021, is a Brazilian pharmaceutical company headquartered in Anápolis, Goiás. The company operates in the medicinal and botanical manufacturing sector, focusing on the production and distribution of pharmaceutical products. Eugia Pharma's mission is to deliver high-quality medications that address unmet medical needs, particularly in specialized areas such as general injectables, oncology, ophthalmics, and hormonal products.

As an importer and distributor, Eugia Pharma plays a significant role in Brazil's pharmaceutical supply chain by sourcing finished pharmaceutical formulations from international suppliers, notably from India. This strategic sourcing enables the company to offer a diverse portfolio of medications to the Brazilian market, ensuring access to essential therapies for various health conditions.

2Distribution Network

Eugia Pharma's distribution network is centered in Anápolis, Goiás, a strategic location that facilitates efficient logistics and access to key markets within Brazil. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, the company's operations suggest a focus on optimizing supply chain processes to ensure timely delivery of pharmaceutical products across the country.

3Industry Role

In Brazil's pharmaceutical supply chain, Eugia Pharma serves as a primary wholesaler and importer, sourcing finished pharmaceutical formulations from international suppliers, particularly from India. By importing a range of medications, including antibiotics and other therapeutic agents, the company ensures a steady supply of essential drugs to meet the healthcare needs of the Brazilian population.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Eugia Pharma Industria Farmaceutica

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Eugia Pharma's sourcing strategy exhibits a high degree of concentration, with a total import value of $3.2 million USD from India over 74 shipments, primarily consisting of two products: Ceftriaxone and Ertapenem. This focused approach indicates a strategic choice to specialize in specific therapeutic areas, potentially allowing for better negotiation terms and streamlined logistics. However, such concentration also poses risks, including supply chain disruptions due to geopolitical issues, regulatory changes, or supplier-specific challenges. The company's reliance on a limited number of suppliers may impact its ability to adapt to market fluctuations or diversify its product offerings.

2Supply Chain Resilience

Eugia Pharma's supply chain resilience is closely tied to its sourcing strategy. The company's dependence on a narrow range of products and suppliers suggests limited diversification, which could affect its ability to respond to supply chain disruptions. Additionally, the lack of publicly available information regarding backup suppliers and the regulatory compliance status of key suppliers further underscores potential vulnerabilities. To enhance resilience, Eugia Pharma may consider diversifying its supplier base and product portfolio, thereby mitigating risks associated with over-reliance on specific sources.

Importing Pharmaceuticals into Brazil — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Brazil

1Regulatory Authority & Framework

In Brazil, the primary regulatory authority overseeing pharmaceutical products is the Agência Nacional de Vigilância Sanitária (ANVISA). ANVISA is responsible for ensuring the safety, efficacy, and quality of health-related products and services, including the authorization of clinical trials, active pharmaceutical ingredients (APIs), and marketing authorizations for drugs and biological products. (gov.br)

Key legislation governing pharmaceutical imports includes Law 9.882/1999, which outlines the regulatory framework for health surveillance in Brazil. This law establishes the procedures for product registration, importation, and commercialization, ensuring that imported pharmaceutical products meet the necessary standards for public health protection.

2Import Licensing & GMP

Import licensing requirements in Brazil are stringent, with ANVISA mandating that all pharmaceutical products imported into the country must be registered and authorized for sale. This process involves submitting comprehensive documentation to demonstrate compliance with Brazilian health regulations. Good Manufacturing Practices (GMP) certification is a critical component of this process, as it ensures that manufacturing facilities adhere to internationally recognized standards for product quality and safety. ANVISA aligns its GMP guidelines with the Pharmaceutical Inspection Co-operation Scheme (PIC/S), adopting the PIC/S Guide to Good Practices for the Manufacture of Medicinal Products. (gov.br)

Eugia Pharma Industria Farmaceutica — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Eugia Pharma's focus on importing advanced antibiotics, specifically Ceftriaxone and Ertapenem, aligns with the company's mission to address critical healthcare needs in Brazil. The demand for these antibiotics is driven by their effectiveness in treating a range of serious infections, making them essential components of hospital formularies and outpatient treatment regimens. By concentrating on these products, Eugia Pharma can leverage its expertise and supplier relationships to ensure a reliable supply of high-quality medications to the Brazilian market.

2Sourcing Profile

Eugia Pharma's sourcing strategy is centered on importing generic drug formulations from India, focusing on specific therapeutic areas such as advanced antibiotics. This approach allows the company to offer cost-effective alternatives to branded medications, thereby increasing accessibility for patients. India's robust pharmaceutical manufacturing sector, characterized by its adherence to international quality standards, makes it a preferred sourcing destination for Eugia Pharma.

3Market Positioning

Eugia Pharma's product mix positions it to serve the hospital and wholesale distribution segments of the Brazilian pharmaceutical market. By supplying essential antibiotics and other critical medications, the company plays a pivotal role in ensuring that healthcare providers have access to necessary treatments for their patients. This positioning underscores Eugia Pharma's commitment to enhancing healthcare delivery in Brazil through the provision of high-quality pharmaceutical products.

Seller's Guide — How to Become a Supplier to Eugia Pharma Industria Farmaceutica

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Eugia Pharma, particularly those offering high-quality generic formulations in therapeutic areas aligned with Eugia Pharma's focus. Potential gaps in Eugia Pharma's current sourcing include the need for additional suppliers to diversify its product portfolio and mitigate supply chain risks. Indian exporters can explore these opportunities by ensuring compliance with ANVISA's regulatory requirements and demonstrating the quality and efficacy of their products.

2Requirements & Qualifications

Indian exporters seeking to supply Eugia Pharma must ensure that their products are registered with ANVISA and comply with Brazilian health regulations. This includes obtaining GMP certification recognized by ANVISA, such as those aligned with PIC/S guidelines. Additionally, exporters must adhere to labeling requirements, including providing information in Portuguese and meeting serialization mandates. Establishing a local partner in Brazil is also essential for facilitating the importation and distribution process.

3How to Approach

Frequently Asked Questions — Eugia Pharma Industria Farmaceutica

What products does Eugia Pharma Industria Farmaceutica import from India?

Eugia Pharma Industria Farmaceutica imports 2 pharmaceutical products across 1 categories. Top imports: Ceftriaxone ($2.1M), Ertapenem ($1.1M).

Who supplies pharmaceuticals to Eugia Pharma Industria Farmaceutica from India?

Eugia Pharma Industria Farmaceutica sources from 2 verified Indian suppliers. The primary supplier is Aurobindo Pharma Limited (81.1% of imports, $7.1M).

What is Eugia Pharma Industria Farmaceutica's total pharmaceutical import value?

Eugia Pharma Industria Farmaceutica's total pharmaceutical import value from India is $3.2M, based on 74 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Eugia Pharma Industria Farmaceutica focus on?

Eugia Pharma Industria Farmaceutica imports across 1 categories. The largest: Advanced Antibiotics (100.0%).

Get Full Eugia Pharma Industria Farmaceutica Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.